Pharmaceutical Knowledge Commons for the Most Neglected Populations in Global Health : The Drugs for Neglected Diseases initiative

個数:
  • 予約

Pharmaceutical Knowledge Commons for the Most Neglected Populations in Global Health : The Drugs for Neglected Diseases initiative

  • 現在予約受付中です。出版後の入荷・発送となります。
    重要:表示されている発売日は予定となり、発売が延期、中止、生産限定品で商品確保ができないなどの理由により、ご注文をお取消しさせていただく場合がございます。予めご了承ください。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 304 p.
  • 言語 ENG
  • 商品コード 9780198905295

Full Description

In Pharmaceutical Knowledge Commons for the Most Neglected Populations in Global Health Fraundorfer presents an in-depth study of how the Drugs for Neglected Diseases initiative (DNDi) has reshaped the global politics of neglected tropical diseases over the past twenty years. By weaving together concepts from different academic disciplines (commons, common goods, orchestration, and healthcare innovation ecosystems) into a novel theoretical framework for the analysis of transformational change in global health, the author argues that DNDi has orchestrated pharmaceutical knowledge commons to produce novel treatments and other knowledge for neglected tropical diseases as common goods.

Focusing on three neglected tropical diseases (NTDs) that have particularly affected neglected populations in the global south - Chagas disease, the leishmaniases, and sleeping sickness - this volume examines the strengths and weaknesses of DNDi's collaborative governance model and illustrates how pharmaceutical knowledge commons help conceptualize processes of innovative transformation in global health to serve the common good.

The Drugs for Neglected Diseases initiative (DNDi) was created in 2003 and developed a not-for-profit approach that would put neglected patients, rather than profits, first. In the past two decades, DNDi has consolidated its alternative pharmaceutical model, showing how to develop novel treatments for a range of neglected tropical diseases and empower R&D (research and development) communities from NTD-endemic countries. Despite these achievements, DNDi's political role in global health has remained underexplored.

最近チェックした商品